retatrutide triple agonist glp-1 gip glucagon phase 2 obesity trial just had its biggest data year yet. In 2026, Eli Lilly's GLP-1/GIP/glucagon receptor posted two major 3 readouts: TRIUMPH-1 (obesity, 2,339 participants) showed a 28.3% average body weight Retatrutide dose: the complete guide

The NTS itself contains GLP-1 producing neurons which signal to decrease food-based reward in the mesolimbic VTA and NAc, which in turn impact memory and emotional processing in the hippocampus and amygdala [40]

BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia

A life I fought hard to keep

As of January this year, California, New Hampshire, Pennsylvania and South Carolina ended Medicaid GLP-1 drug coverage for weight loss, and Michigan started restricting coverage to people classified as morbidly obese, meaning they have a body mass index above 40